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Summary.- OBJECTIVES: The aim of this study was 
to evaluate the influence of retransplantation in graft and 
recipient survival.
METHODS: We carried out a retrospective study 
in 419 renal transplants and studied the influence of 
retransplantation in graft and patient survival.
A homogeneity study was performed between the two 
groups with a Student`s T and a chi-square tests. Graft 
survival analysis was performed with Kaplan-Meyer and 
log rank tests.
RESULTS: Of 419 transplants, 370 (88.3%) were first 
transplantations, 45(10.7%) second transplantations 
and 4(1%) third ones. Mean follow-up of the whole 
group was 72.5 months (+/-54.1 SD).
There were no differences in follow-up between groups 
(Mean Follow-up 73.1 months +/-54.4 SD in first 
transplantations vs. 61.6 months +/-51.2 SD in repeat 
transplantation. p >0.05). The actuarial graft survival 
showed no differences between patients with first 
transplantation and those with a repeat one. [3 and 5-
year SV of 89% (95% CI: 87-91%) and 84% (95% CI: 
82-86%) Vs 88% (95% CI; 83-93%) and 85% (95% CI; 
80-90%) respectively].
After adjusting for all the heterogeneity variables we still 
did not find differences on graft survival.
The actuarial recipient survival showed no differences 
between patients with first transplantation and those with 
a repeat one. [3 and 5 year SV of 98% and 96% Vs. 
97%].
CONCLUSIONS: There are no differences of graft 
and recipient survival between patients with a first 
transplantation and those with a repeat one.
Keywords: Survival. Retransplantation. Renal 
transplantation. Graft.
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INTRODUCTION
 In spite of the fact that in the last times the 
long-term grafts functional results have improved, the 
chronic rejection is still the main problem in the renal 
transplantation current scenario (1). The transplanted 
patient with the pass of time presents a graft func-
tion deterioration that inevitably carries the dialysis 
substitution, needing in some cases to be transplanted 
along his life in more occasions. 
 Retransplantation suppose a new surgical 
aggression that together with the new dialysis wai-
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ting time , they might reduce both recipient and graft 
survival.
 The percentage of candidates in waiting-list 
for retransplant is increasing, being up to 20-30 % 
in some series. This situation and the fact that the 
absolute contraindications for a new transplant have 
diminished notably, makes us wonder in wich cases 
we should offer the patient with chronic renal insuffi-
ciency this type of treatment (2).
 The benefit in terms of survival after receiving 
the first transplant in comparison with remaining on 
dialysis is clearly demonstrated but when a retrans-
plant is received the studies are not so conclusive 
(3,4).
 Our aim is to evaluate if a second or third 
transplant has any influence on graft survival and if 
there exist differences in global recipient survival bet-
ween these groups.
MATERIAL AND METHODS
 We realize an analytical, observational and 
retrospective study of 419 consecutive renal trans-
plantations realized between 1994 and 2010. We 
study the influence of the retransplant in graft survival 
and in the recipient one. 
 The first transplant was realized preferably 
in the right iliac fossa whereas in case of the second 
ones it was chosen the left iliac fossa. In the third 
transplants it was performed a  transplant nephrec-
tomy of the first graft ,placing the new graft in iliac 
right fossa. All the transplants were heterotopics ones. 
Transplantation was carried out using a standardized 
surgical technique as described in a recent study (5). 
The clinical and pathological variables are shown 
in the table 1.They were obtained from the hospital 
records. Body mass index (BMI) was calculated as 
the quotient of weight in kilograms divided by the 
square of the height in meters.The acute rejection was 
confirmed by biopsy and with the improvement of the 
renal function after corticosteroids administration. The 
surgical complications were confirmed by ultrasono-
graphy, computerized tomography or surgical explo-
ration.
Statistical analysis  
 The primary end-point of the study was failure 
of the graft, defined as the development of end-stage 
renal failure requiring the reestablishment of dialysis 
for the graft survival analysis and the death of reci-
MÉTODOS: Analizamos retrospectivamente 419 tras-
plantes renales consecutivos realizados entre 1994 y 
2010, analizando la influencia del retrasplante en la 
supervivencia del injerto renal. Se ha realizado un es-
tudio de homogeneidad de los dos grupos mediante 
Tablas de contingencia para las variables cualitativas 
y t de student para las cuantitativas. La supervivencia 
y comparación de supervivencia con Kaplan-Meyer y 
log-rank.
RESULTADOS: De los 419 trasplantes, 370 (88,3%) 
fueron primeros trasplantes 45(10,7%) segundos tras-
plantes y 4(1%) terceros. Media de seguimiento de todo 
el grupo de 72,5 meses (+/- 54,1 DE) y mediana de 
68,8 meses( Rango de 0 a 188 meses ).
No existen diferencias en el tiempo de seguimiento (Me-
dia del grupo de pacientes con un solo trasplante de 
73,1 meses +/-54,4DE Vs. 61,6 meses +/-51,2DE 
del grupo de pacientes retrasplantados. p >0,05).
El análisis de la supervivencia actuarial del injerto reve-
la que no existen diferencias estadísticamente significa-
tivas entre los pacientes con un primer trasplante y los 
retrasplantados [SPV 89% (95% IC; 87- 91%) y 84% 
(95% IC; 82-86%) a los 3 y 5 años frente a 88% (95% 
IC; 83-93%) a los 3 años y 85% (95% IC; 80-90%) a 
los 5 años]. Al ajustar por las variables para las que los 
grupos no fueron homogeneos las diferencias se siguen 
manteniendo.
El análisis de supervivencia de los receptores revela 
que tampoco existen diferencias entre los dos grupos 
[SPV del 98% y 96% a los 3 y 5 años en los primeros 
trasplantes frente a 97% a los 3 años y 5 años en los 
retrasplantados].
CONCLUSIONES: No existen diferencias en la super-
vivencia del injerto ni en la de los receptores entre pa-
cientes trasplantados por primera vez y aquellos que 
reciben un retrasplante.
Palabras clave: Supervivencia. Retrasplante. 
Trasplante renal. Injerto.
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Recipient age (years)
Donor age (years)
Recipient BMI (kg/m2)
Donor BMI (kg/m2)
Residual diuresis (cc)
Cold ischemia time (hours)
Donor ICU stay (days)
HLA matches
Pre-transplant dialysis duration (months)
Men 
Functioning grafts
Delayed graft function 
Smoker 
Acute rejection
Immediate surgical re-interventions
Surgical complications 
Recipient arterial hypertension
Recipient dyslipidemia
X-ray vascular calcification 
Ventricular hypertrophy 
Dialysis type
Predialysis 
CAPD 
Hemodialysis
CAPD+Hemodialysis
Immunosuppressant drugs
Cyclosporin + mofetil mycophenolate
Cyclosporin + azathioprine
Tacrolimus + mofetil mycophenolate
Cyclosporin + sirolimus
Cyclosporin + everolimus
Other therapies
Original renal disease
Polycystic kidney disease
Glomerulonephritis
Diabetic nephropathy
Obstructive uropathy
Autoimmune diseases
Chronic pyelonephritis
Nephroangiosclerosis
Tubulo-Interstitial nephritis
Idiopathic
Other
Cause of death:
Cardiovascular origin
Infectious origin
Neoplasm
COPD
Digestive complication
Neurologic disease
Hepatopathy
Cranioencephalic trauma
Unknown origin
N
419
417
375
119
288
413
212
407
418
N
419
419
419
419
419
419
419
419
419
393
302
419
418
419
33
Mean
49,9
48,1
25
25,4
842
14,5
2,6
2,2
31,7
N/%
256(61,1%)
328 (78,3%)
89 (21,2%)
73 (17,4%)
180 (43%)
42 (10%)
147 (35,1%)
332(79,2%)
123 (29,4%)
84(20%)
134(32%)
23 (5,5%)
72 (17,2%)
307 (73,3%)
17 (4,1%)
120 (28,6%)
71 (16,9%)
181(43,2%)
12 (2,9%)
10 (2,4%)
24 (5,7%)
81 (19,3%)
98 (23,4%)
33 (7,9%)
18 (4,3%)
12 (2,9%)
35(8,4%)
43 (10,3%)
26 (6,2%)
53 (12,6%)
20 (4,7%)
16 (3,8%)
3 (0,7%)
6 (1,4%)
1(0,2%)
2(0,5%)
1(0,2%)
1(0,2%)
1(0,2%)
2(0,5%)
DS
+/-13,9
+/-18,3
+/-4
+/-3,9
+/-719
+/-7,3
+/-3,1
+/-0,9
+/-44,2
TABLE I. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF THE STUDY GROUP.
Abbreviations:  BMI = Body mass index; ICU = Intensive Care Unit; CAPD = Continuous Ambulatory Peritoneal Dialysis; HLA: 
Human leukocyte antigen; COPD= Chronic obstructive pulmonary disease.
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pient for the recipient survival analysis. Kaplan-Meier 
survival analysis was used to examine graft  and re-
cipient survival, and the log-rank test was used for 
evaluating differences between curves. 
 Comparisons between the groups with first or 
repeated transplantation were made with student’s t 
test for continuous variables and with chi-square test 
for categorical variab To adjust for the quantitative 
variables that were not distributed homogeneously 
between both groups we realize a Cox univaried sur-
vival study stratifying the previous variables. For the 
qualitative variables a stratified Kaplan-Meier’s me-
thod survival analysis was realized.
 All statistical analyses were carried out using 
the SPSS program version 15.0 (SPSS Inc., Chicago, 
Illinois, USA). Results were considered statistically sig-
nificant if the p value was less than 0.05.
RESULTS
 Of 419 transplants, 370 (88,3 %) were first 
ones, 45 (10,7 %) second  and 4 (1 %) third ones. Fo-
llow-up mean of the whole group of 72,5 months (+/-
54,1 SD) and median of 68,8 months (Range from 0 
to 188).
 The remainig clinical and pathological varia-
bles of the whole group are shown in the Table I.
Study of homogeneity between first transplantations 
and repeated transplantations.
 Both groups were homogeneous in relation 
to the clinical and pathological variables summarized 
in Tables II and III. There are no differences in the 
follow-up time of  both groups (Follow-up mean of 
first transplantations of 73,1 months +/-54,4 SD vs. 
61,6 months +/-51,2 SD in the retransplanted pa-
tients group; p> 0,05).
 The patients who received the first transplan-
tation were older, had a major residual diuresis and 
a major percentage of dyslipidemia, whereas the the 
retransplanted ones had a major use of monoclonal 
antibody induction, longer previous dialysis time and 
a better HLA matching.
 The retransplanted patients belong to more 
recent cohorts in time. For this reason this group mig-
ht followt a more modern immunosuppressive regime 
based on tacrolimus. This situation may improve the 
graft survival of the retransplanted group producing 
important bias. To solve this problem we include this 
variable in the homogenity study. The retransplanted 
patients presented a major frequency a of immuno-
suppression based on tacrolimus in comparison with 
first time transplantation group; HR=4,9.
Graft survival analysis
 At the end of the study, 289 (78,1 %) grafts 
had function in the group of first transplants and 39 
(79,6 %) in  the retransplantation group.
 The actuarial graft survival analysis didn´t 
show significant statistical differences between the 
patients receiving a  first transplant and those who 
received a second or third one. [SV 89 % (95%CI; 
87-91 %) and 84%(95%CI; 82-86%) 3 and 5 years 
opposite to 88%(95%CI; 83-93%) at 3 years and 85 
% (95%CI; 80-90 %) at 5 years. 
 In Figure 1 we can appreciate how the survi-
val between both groups is similar along the time.
 As we saw in the homogeneity study, the re-
transplanted patients presented a major frequency of 
immunossupresive therapy  based on tacrolimus. For 
this reason we decided to repeat the survival analysis 
adjusting and stratifying for this variable. The survival 
analysis reveals that there are no differences between 
both groups after realizing the adjustment (p> 0,05). 
In the group of patients with Tacrolimus the survival 
at 3 years was 88 % and 84 % at 5 years in the first 
transplants vs 89 % at 3 and 5 years in the retrans-
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FIGURE 1. Graft survival graphic of patients with first 
transplantation and retransplanted ones.
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TABLE II.  DEMOGRAPHIC AND CLINICAL CUANTITATIVE VARIABLES ACCORDING TO THE NUMBER OF 
TRANSPLANTATION.
Recipient age (years)
Residual diuresis (cc)
HLA matches
Previous dyalisis time(days).
Donor age (years)
Donor ICU stay (days)
Cold ischemia time (hours)
DonorCreatinine.
Recipient BMI (kg/m2)
Donor BMI (kg/m2)
First Transplantation
(X+/-SDE)
50+/-13,8
898,7+/-713
2,2+/-0,9
768+/-1009
48,3+/-18,4
2,6+/-3,1
14,6+/-7,5
1+/-0 ,4
25,1+/-4,1
25,6+/-4
Retransplantation
(X+/-SD)
46+/-13,5
395+/-601,7
2,5+/-1
2349+/-2290
46,2+/-17,7
2,8+/- 3,6
14,1+/-6,1
0,9+/-0,2
23,8+/-3
24,4+/-2,8
P
0,036
<0,001
0,02
<0,001
>0,05
>0,05
>0,05
>0,05
>0,05
>0,05
TABLE III.  DEMOGRAPHIC AND CLINICAL CUALTITATIVE VARIABLES ACCORDING TO THE NUMBER OF
TRANSPLANTATION.
X-ray vascular calcification
Surgical complications
Recipient dyslipidemia
Diabetes Mellitus I
Diabetes Mellitus II
Smoker
Recipient arterial hypertension
Acute rejection
Men
Delayed graft function.
Monoclonal antibody induction 
Immunosupression
    Tacrolimus
    Others
First Transplantation
61(19,9%)
128(34,6%)
107(28,9%)
25(6,8%)
13(3,9%)
135(36,6%)
288(77,8%)
162(43,8%)
226(61,1%)
76(20,5%)
19(5,1%)
167(45,5%)
200(54,5%)
Retransplantation
15(32,6%)
19(38,8%)
16(32,7%)
5(10,2%)
3(6,1%)
10(20,4%)
44(89,8%)
18(36,7%)
30(61,2%)
13(26,5%)
10(20,4%)
30(62,5%)
18(37,5%)
P(Chi- square)
>0,05
>0,05
0,019
>0,05
>0,05
>0,05
>0,05
>0,05
>0,05
>0,05
<0,001
0,027
Abbreviations: BMI= Body mass index; ICU= Intensive Care Unit; HLA: Human leukocyte antigen
Comparación de proporciones mediante chi cuadrado.
planted ones. The group that received other immuno-
supresive therapies had a survival at 3 and 5 years 
of 92 % and 86 % respectively in the first transplants 
vs. 87 % and 81 % in the re-transplanted ones.
    We decided to adjust  for the recipient age , time 
on dyalisis and the HLA matching. The univaried 
study did not find survival differences between first 
transplants and retransplantations. We think that the 
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residual diuresis and the dyslipidemia weren´t rele-
vant parameters and they were not include in this 
analysis.
Recipients survival analysis 
 In the group of first transplantations there 
were 31 events (8,1 %) whereas in the retransplanta-
tion group there were 2 (4,1 %). The analysis did not 
find statistical differences of  mortality between both 
groups as it is shown in the Table IV.
DISCUSSION
 It is an objective fact that the number of pa-
tients candidates for a retransplant and the number 
of the second transplants realized in the last years 
for all kinds of organs have increased drastically. In 
The United States the candidates for receiving a new 
transplant of organs supposed 9,5 % of the total of 
patients in waiting-list in 2007 and an increase from 
2.322 to 4.553 patients took place in comparison 
with 1990 (6). The principal reason for this situation 
is the unstoppable loss of grafts related with chronic 
rejection. It is thought that in 5 years after the trans-
plantation a 30 % graft lost is possible (7).
 It is a fact that the benefit of the transplant in 
comparison with the dialysis exists for a great variety 
of patients groups but the beneffoit of the retransplan-
tation is not so well studied. 
 A high risk profile was assumed for the re-
transplanted patient due to his trend to the develop 
antibodies and  allosensibilization presenting a hig-
her risk of acute  rejection. For this reason, traditio-
nally the graft survival following a retransplant was 
considered to be lower in comparison with a first one 
(8-11). In addition, up to date it does not exist agree-
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ment on the limit of transplants that a patient can ma-
nage and to there is not a clear cut point for it. 
 On the other hand, the benefit of the trans-
plant changes depending on the causative pathology 
of the chronic renal insufficiency and the recipient risk 
factors, so it seems to be reasonable that we question 
wich patients are good candidates to receive a re-
transplant. For this reason we must consider, the qua-
lity of life, the surgical mortality and the costs of the 
different therapeutic alternatives to inform the patient 
and offer him the best possible option (12).
 In our case, we have analyzed if graft func-
tion and the recipient survival of the retransplanted 
patients are comparable with those of first time trans-
planted. As limitation of this study we emphasize that 
we could not obtain data of immunosuppressive drugs 
blood levels neither the panel reactive antibody (PRA) 
percentage, factors of clear relevancy in graft future. 
Nevertheless the use of a monoclonal antibody induc-
tion  is an indirect reflection of a worse immunologi-
cal profile in the the retransplanted group. This worse 
immunological profile would be related in any case 
with worse graft survival results in the retransplanted 
group and as we saw thosw results were not found.
 In the case of graft survival, our analysis 
shows that there are no differences at 3 and 5 years 
between both groups after the adjustment for the clini-
cal and pathological variables in which heterogenei-
ty was discovered. 
 The literature in this field finds works with 
contradictory results , but the big series affirm that 
these grafts offer similar results in functional and sur-
vival terms. In fact, the first organ transplantations in 
general present a better survival of the graft in com-
parison with the retransplants and it is in the case 
of the cadaveric renal transplantation where a major 
polemic exists. 
First transplantation
Retransplantation
Survival at 3 years
98%
97%
95% IC
97-99%
95-99%
Survival at 5 years
96%
97%
95% IC
95-97%
95-99%
p
> 0,05
TABLE IV. ACTUARIAL RECIPIENT SURVIVAL ACCORDING TO THE NUMBER OF TRANSPLANTATIONS.
Análisis mediante Kaplan-Meier y log rank.
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 Magee et al analysed the Organ Procure-
ment and Transplantation Network (OPTN)database 
with 35.340 living donor transplants and 48. 351 
cadaveric ones. The percentage of retransplantation 
was 7,1 % and 9,7 % respectively. They estimated 
that the living donor retransplantation presented a 
significatively lower survival at 1, 3 and 5 years com-
pared with those who received the first transplantatio 
of these kind of donors (93 %, 83 % and 76 % vs 95 
%, 89 % and 81 %. P> 0,0001) with a very similar 
trend in the case of the cadaveric donors grafts (13).
Rao et al analyzed the renal retransplantations reali-
zed between 1990-2007 estimating a clear increase 
of the same ones from 1.293 to 1.867 patients per 
year. They support that the graft survival at 5 years 
seems to be similar for both groups in case of the 
renal transplantation with cadaveric donor grafts (70 
% vs. 69 %, p = 0.5) (6).
 Gruber et al realized a study with 166 trans-
plantations(26 retransplantations) in a Afro-American 
population. They concluded that graft and patient sur-
vival at 1 year was similar in both groups (14).
 In the case of our recipient survival analysis, 
we either do not find differences. We admit that the 
low number of deaths in the group of retransplanted 
patients and a short follow-up carries less solid con-
clusions.
 The following step ,would be to analyze if 
a real benefit exists in the recipient  survival with the 
retransplantation compared with those  who stay in 
dialysis. In our case, we do not realize this compa-
risons due to the fact that we do not have a trans-
planted patient cohort with a graft failure remaining 
in dialysis. We assume that the clearly demonstrated 
benefit that offers the first transplant compared with 
the permanency in dialysis is kept once the new trans-
plantation is performed as it is reflected in most of the 
scientific literature.
 Related with this issue, Rao et al evaluated 
the benefit in survival terms of the retransplantation. 
They studied 3.067 patients who received a trans-
plantation and they were actually in dialysis caused 
by graft failure.  Of them 1.163 received a new trans-
plant. His results show us that retransplantation is as-
sociated with a mortality decrease of 50 % compared 
with the group that remained in dialysis (HR:0,54; 
p <0,0001). This benefit was higher in the patient´s 
subgroup between 18 and 59 years. The risk of dea-
th in the retransplant group was only major during the 
first post-surgery month (HR:1,66; p=0,048) (15).
 Similar conclusions are shown on the work 
performed by Ojo et al. They found that the retrans-
plant was associated with a 45 % and 23 % mor-
tality reduction at 5 years in diabetic patients type 
one and no diabetics respectively. These groups were 
compared with transplanted patients who returned to 
the waiting list (12). Miles et al studied the impact 
of the retransplantation in grafts recipients of Expan-
ded Criteria Donors (ECD) and those who received 
conventional donors ones. They studied 2.908 trans-
plants(292 with “ECD” grafts). In the case of the ECD 
kidneys the patients survival was similar to those that 
remained in dialysis whereas those who received a 
conventional kidney they presented a reduction of the 
mortality (HR=0.44; p <0.0001) (16).
 In addition the majority of studies agree that 
after the first graft failure, the new dialysis entry su-
pposes a notable increase in mortality. Especially in 
case of the diabetic patients who present an added 
risk in this period (17-20).
 For all these reasons whenever a patient is 
considered to receive a new transplant it is necessary 
to take notice of both  own recipient  and donor fac-
tors becouse we won´t reach in all the cases the same 
survival benefits.
CONCLUSIONS
 Due to the increasing number of patients can-
didates for a new transplant in the  waiting-list, it is 
important to study the graft and recipient survival be-
nefit with the new transplant.
 Globally the retransplant continues being 
such a good treatment for the patient with renal in-
sufficiency as it is the first transplant, so it must be 
offered when the necessary conditions are fulfilled.
 In our case we can affirm that graft and re-
cipient survival differences do not exist between first 
time transplanted patients and those that receive a 
retransplant. 
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